Foreign interests (re leronlimab) - instead of knocking, they could (if they so desired) end up "owning the door" and deciding where they want to put that door, LOL. As previously mentioned, Cytodyn's market cap is not an exceptionally high number - less than $ 2 bil. There's a lot of wealth out there and some savy folks.
Our BP better wise up fast, or find themselves facing a far more formidable enterprise, competing with them every step of the way...and with leronlimab, vs their drugs, laden with nasty side effects,...guess who comes out on top?
Strange days, indeed!
News 
Market Data 
Discover 
AI
